Document is current
Any future updates will be listed below
-
Authors
Jeong, Jongwon
Park, Jun-Kook
Shin, Jiwon
Jung, Inseong
Kim, Hyun-Woo
Park, Anyeseu
Cho, Hanchae
Kang, Sung-Min
Shin, Sanghee
Park, Eunju
Kim, Jisuk
Noh, Soojeong
Ahn, Yongdeok
Kim, Do-Kyun
Lee, Jeong Yoon
Seo, Daeha
Baek, Moon-Chang
Yea, Kyungmoo https://orcid.org/0000-0002-3755-4520
-
Funding
Funding for this research was provided by:
National Research Foundation of Korea(NRF) grant funded by the Korea government (2020M3A9I4039539)
National Research Foundation of Korea(NRF) grant funded by the Korea government (RS-2021-NR060094)
National Research Foundation of Korea(NRF) grant funded by the Korea government (RS-2023-NR077266)
Basic Science Research Program through the NRF of Korea funded by the Ministry of Education (RS-2024-00450383)
DGIST Program of the Ministry of Science and ICT (21‐DGRIP‐01)
- License Information
-
More Information
Article History
Received: 30 March 2025
Accepted: 15 August 2025
First Online: 22 August 2025
Declarations
:
: All in vivo experimental protocols were ethically approved by the DGIST Institutional Animal Care and Use Committee (IACUC; approval number: DGIST-IACUC-24010205-0000; project title: Development of Novel Therapeutic strategies for Acute Respiratory Distress Syndrome (ARDS) using mesenchymal stem cell-derived exosomes; date of approval: 2024-01-02). Human adipose-derived mesenchymal stem cells (hADMSCs) used in this study were purchased from CEFObio (Seoul, Republic of Korea), which confirmed that the cells were originally collected under appropriate ethical approval, and that the donors had provided written informed consent. THP-1 (TIB-202), A549-Luc2 (CCL-185-LUC2), and Vero E6 (CRL-1586) cell lines were obtained from the American Type Culture Collection (ATCC). According to ATCC, these cell lines were acquired under appropriate ethical approval and donor informed consent.
: Not applicable.
: The authors declare that they have no competing interests.
